<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="13404"><DrugName>tesmilifene</DrugName><DrugNamesKey><Name id="42750305">tesmilifene</Name><Name id="42750309">tesmilifene hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>DPPE</Value></Name><Name><Value>tesmilifene</Value><Types><Type>INN</Type></Types></Name><Name><Value>BMS 217380-01</Value></Name><Name><Value>BMY-33419</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>DPPE hydrocloride</Value></Name><Name><Value>tesmilifene hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>DPPE, BMS</Value></Name><Name><Value>anticancer, BMS/Manitoba Univ/MTCR</Value></Name><Name><Value>BMS-217380</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>YMB-1002</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>98774-23-3</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>92981-78-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20614">University of Manitoba</CompanyOriginator><CompaniesSecondary><Company id="15123">Bristol-Myers Squibb Canada Inc</Company><Company id="19896">Shin Poong Pharmaceutical Co Ltd</Company><Company id="20614">University of Manitoba</Company><Company id="24845">YM BioSciences Inc</Company><Company id="29954">TTY Biopharm Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="13404" type="Drug"><TargetEntity id="109897" type="siDrug">Tesmilifene hydrochloride</TargetEntity></SourceEntity><SourceEntity id="15123" type="Company"><TargetEntity id="5000259155" type="organizationId">Bristol-Myers Squibb Canada</TargetEntity></SourceEntity><SourceEntity id="19896" type="Company"><TargetEntity id="4295881859" type="organizationId">Shinpoong Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="20614" type="Company"><TargetEntity id="4296568475" type="organizationId">University of Manitoba</TargetEntity></SourceEntity><SourceEntity id="24845" type="Company"><TargetEntity id="4295861723" type="organizationId">Ym Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="29954" type="Company"><TargetEntity id="4295891167" type="organizationId">TTY Biopharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="127" type="ciIndication"><TargetEntity id="C16" type="ICD10"></TargetEntity><TargetEntity id="151" type="ICD9"></TargetEntity><TargetEntity id="10017758" type="MEDDRA"></TargetEntity><TargetEntity id="D013274" type="MeSH"></TargetEntity><TargetEntity id="-2031094615" type="omicsDisease"></TargetEntity><TargetEntity id="646" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="202" type="ciIndication"><TargetEntity id="C22" type="ICD10"></TargetEntity><TargetEntity id="10019695" type="MEDDRA"></TargetEntity><TargetEntity id="D008113" type="MeSH"></TargetEntity><TargetEntity id="-897418746" type="omicsDisease"></TargetEntity><TargetEntity id="610" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="198" type="Action"><TargetEntity id="195" type="Mechanism">Histamine Receptor Antagonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="127">Stomach tumor</Indication><Indication id="202">Liver tumor</Indication><Indication id="276">Prostate tumor</Indication><Indication id="49">Breast tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="198">Histamine receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1586">Anticancer chemosensitizer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>R6</Code><Name>SYSTEMIC ANTIHISTAMINES</Name></Ephmra></EphmraCodes><LastModificationDate>2017-12-01T16:28:28.000Z</LastModificationDate><ChangeDateLast>2017-12-04T00:00:00.000Z</ChangeDateLast><AddedDate>1996-09-20T11:32:48.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="24845" linkType="Company"&gt;YM Biosciences&lt;/ulink&gt; (formerly York Medical), &lt;ulink linkID="29954" linkType="Company"&gt;TTY Biopharm&lt;/ulink&gt; and &lt;ulink linkID="19896" linkType="Company"&gt;Shin Poong Pharmaceutical&lt;/ulink&gt; were developing tesmilifene (N,N-diethyl-2-[4(phenylmethyl)phenoxy]ethanamine; DPPE; BMS-217380), an iv intracellular histamine antagonist chemopotentiator (for taxanes and anthracyclines) licensed from the &lt;ulink linkID="20614" linkType="Company"&gt;University of Manitoba&lt;/ulink&gt;, for the treatment of several cancers, including breast, prostate, gastric cancer and hepatic [&lt;ulink linkID="389716" linkType="reference"&gt;389716&lt;/ulink&gt;], [&lt;ulink linkID="581527" linkType="Reference"&gt;581527&lt;/ulink&gt;], [&lt;ulink linkID="506646" linkType="Reference"&gt;506646&lt;/ulink&gt;].  In March 2004, YM initiated phase III trials in the US and Europe for  metastatic breast cancer [&lt;ulink linkID="529777" linkType="reference"&gt;529777&lt;/ulink&gt;]; however, in January 2007, the trial was terminated as the DSMB advised it was unlikely to demonstrate a survival benefit. YM said it would review of the data and consider the options  [&lt;ulink linkID="761775" linkType="Reference"&gt;761775&lt;/ulink&gt;]. In September 2007, YM reported it would not undertake further clinical development of tesmilifene because the breast cancer trial was unlikely to achieve its primary endpoint, although ongoing trials would run their course [&lt;ulink linkID="832655" linkType="Reference"&gt;832655&lt;/ulink&gt;]. No further development has been reported by  TTY and Shin Poong.&lt;/para&gt;&lt;para&gt;The compound had previously been licensed to &lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; [&lt;ulink linkID="218937" linkType="reference"&gt;218937&lt;/ulink&gt;]; however, by November 2000, YM had acquired exclusive rights  [&lt;ulink linkID="389716" linkType="reference"&gt;389716&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In February 2006, the FDA awarded Fast Track designation for tesmilifene, for use in combination with an &lt;ulink linkID="7975" linkType="Drug"&gt;anthracycline&lt;/ulink&gt;, for the treatment of advanced breast cancer [&lt;ulink linkID="649947" linkType="Reference"&gt;649947&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;BREAST CANCER&lt;/subtitle&gt;In March 2004, a phase III trial, to be conducted in 65 to 70 centers across North America and Europe, was initiated in women with metastatic breast cancer. The study was to compare the overall survival rate resulting from administration of tesmilifene in combination with anthracycline, &lt;ulink linkID="13022" linkType="Drug"&gt;epirubicin&lt;/ulink&gt; or cyclophosphamide, against administration of epirubicin or cyclophosphamide, alone. At that time, enrollment was expected to be completed within 18 months.   In  March 2004, YM anticipated approval for breast cancer in 2006 [&lt;ulink linkID="529777" linkType="reference"&gt;529777&lt;/ulink&gt;]. In October 2004, 48 sites had been recruited and a further 38 were expected to be included in the trial. A total of 200 patients were expected to have enrolled by year-end 2004, and enrollment completion was anticipated by the end of March 2005 [&lt;ulink linkID="566163" linkType="Reference"&gt;566163&lt;/ulink&gt;]. By May 2005,  patient enrollment had exceeded 50% of the target and the total enrollment target of 700 patients was anticipated to be met by the third quarter of 2005 [&lt;ulink linkID="601082" linkType="Reference"&gt;601082&lt;/ulink&gt;]. By August 2005, initial results had shown that tesmilifene enhanced the activity of the chemotherapy [&lt;ulink linkID="617040" linkType="Reference"&gt;617040&lt;/ulink&gt;]. By September 2005, the trial had enrolled 662 patients [&lt;ulink linkID="622644" linkType="Reference"&gt;622644&lt;/ulink&gt;].  Later in September 2005, enrollment for this trial was completed, with 723 patients recruited. An interim analysis of data was planned for mid-2006. By that time, the trial included more than 100 sites worldwide [&lt;ulink linkID="625703" linkType="Reference"&gt;625703&lt;/ulink&gt;]. In March 2006,  it was reported that there was a substantial increase in survival for women treated with the combination of  tesmilifene and chemotherapy compared with chemotherapy alone [&lt;ulink linkID="658243" linkType="Reference"&gt;658243&lt;/ulink&gt;]. In June 2006, the trial reached 192 events, triggering an  interim review of the data. The data safety monitoring board (DSMB) determined that the drug was safe and the trial should continue as planned. The board's statistical analysis was expected to be completed within 4 weeks [&lt;ulink linkID="672115" linkType="Reference"&gt;672115&lt;/ulink&gt;]. In June 2006, the board cleared  continuation of the  phase III breast cancer trial  after reviewing interim safety and efficacy  analysis. The second of three interim analyses  was planned in the third quarter of 2006 [&lt;ulink linkID="675753" linkType="Reference"&gt;675753&lt;/ulink&gt;]. In August 2006, the board again cleared the trial to continue [&lt;ulink linkID="685639" linkType="Reference"&gt;685639&lt;/ulink&gt;]. In January 2007, the independent DSMB notified YM that it had completed the 320 events required for a third interim analysis of the trial. At that time, an ongoing data sweep was expected to be completed by February 2007, along with  a formal recommendation from the DSMB [&lt;ulink linkID="757410" linkType="Reference"&gt;757410&lt;/ulink&gt;]. In January 2007, the trial was terminated as the DSMB advised it was unlikely to demonstrate a survival benefit. The review was based on an interim analysis of 351 events. YM said it would review of the data and consider the options  [&lt;ulink linkID="761775" linkType="Reference"&gt;761775&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase III trials had previously been conducted in breast cancer patients; however, the phase III breast cancer program was stopped in 1999 [&lt;ulink linkID="409567" linkType="reference"&gt;409567&lt;/ulink&gt;]. Nevertheless, by October 2002, YM was in the process of finalizing a new trial protocol for a registration study of tesmilifene in metastatic breast cancer [&lt;ulink linkID="467710" linkType="reference"&gt;467710&lt;/ulink&gt;]. In February 2003, the company submitted a protocol for its pivotal trial to the FDA [&lt;ulink linkID="480172" linkType="reference"&gt;480172&lt;/ulink&gt;], and in March 2003, the FDA agreed the study's design and endpoint. At this time, YM said it was on schedule to enroll breast cancer patients during 2003 [&lt;ulink linkID="480733" linkType="reference"&gt;480733&lt;/ulink&gt;]. In June 2003, YM received approval from the FDA to use a sequential design for the analysis of its planned pivotal phase III trial [&lt;ulink linkID="494291" linkType="reference"&gt;494291&lt;/ulink&gt;]. In November 2003, initiation of the pivotal phase III trial was approved [&lt;ulink linkID="511462" linkType="reference"&gt;511462&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase III trial of tesmilifene, in combination with doxorubicin, was being conducted by the &lt;ulink linkID="20519" linkType="Company"&gt;National Cancer Institute&lt;/ulink&gt; of Canada (prior to the license to YM) in metastatic breast cancer patients; however, this study was terminated in 1999. Monitoring of patients from this study continued after this time and phase III trial data were presented at the 37th ASCO meeting in San Francisco, CA, in May 2001. It was shown that patients receiving tesmilifene/doxorubicin combination therapy lived an average of 23.6 months, versus a 15.6 month survival for those subjects receiving doxorubicin alone [&lt;ulink linkID="409567" linkType="reference"&gt;409567&lt;/ulink&gt;]. Data from a further phase III trial of tesmilifene and doxorubicin versus doxorubicin alone, involving 305 patients from Russia and Poland, were also presented at this meeting. This trial was also closed following interim analysis of data [&lt;ulink linkID="409635" linkType="reference"&gt;409635&lt;/ulink&gt;]. Further data were presented in May 2005 at the 41st ASCO meeting in Orlando, FL, from a subgroup analysis of the phase III trial. It was suggested that a differential effect on a minority population of mdr+ cells may explain  a late survival benefit in the absence of an early response for tesmilifene [&lt;ulink linkID="603448" linkType="Reference"&gt;603448&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2005, Shin Poong was planning to initiate a bridging study in breast cancer in South Korea later that year [&lt;ulink linkID="582289" linkType="Reference"&gt;582289&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By February 2005, YM had received regulatory approval for a phase II metastatic breast cancer trial of tesmilifene in combination with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt;; the study was expected to begin by the end of March 2005, and recruitment was to be complete by the end of 2005 [&lt;ulink linkID="584460" linkType="Reference"&gt;584460&lt;/ulink&gt;]. By May 2005, patient screening for this study was underway     [&lt;ulink linkID="601082" linkType="Reference"&gt;601082&lt;/ulink&gt;]. In January 2006, YM entered a collaboration with &lt;ulink linkID="1009547" linkType="Company"&gt;sanofi-aventis&lt;/ulink&gt; to test docetaxel  in combination with tesmilifene in patients with rapidly progressing metastatic cancer. The29-week phase II study was to enroll 39 patients in Europe and the US. Subjects would receive docetaxel every 3 weeks and tesmilifene as a single infusion at the start of each docetaxel cycle [&lt;ulink linkID="644352" linkType="Reference"&gt;644352&lt;/ulink&gt;]. In June 2006, treatment of patients began. At that time, enrollment was expected to be completed in the fourth quarter of 2006 and data was expected to be reported in early and late 2007 [&lt;ulink linkID="671622" linkType="Reference"&gt;671622&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase II trial of tesmilifene in combination with doxorubicin, completed by 1998, the overall response rate in 38 patients was 48.6% (11.4% complete responses and 37.2% partial responses). Neurotoxicity was transient and easily managed by sedation during infusion [&lt;ulink linkID="291067" linkType="reference"&gt;291067&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PROSTATE CANCER&lt;/subtitle&gt;By October 2001, a phase III trial in prostate cancer had been discussed with regulators and was expected to start in mid-2002 [&lt;ulink linkID="435473" linkType="reference"&gt;435473&lt;/ulink&gt;]; however, in June 2002, there was no apparent timeline in place for phase III trials [&lt;ulink linkID="456169" linkType="reference"&gt;456169&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2006, a randomized first-line trial in HRPC patients combining  tesmilifene with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; was being designed; the study was expected to begin before the end of 2006 [&lt;ulink linkID="671622" linkType="Reference"&gt;671622&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2001, YM confirmed that it was recommencing phase II trials with tesmilifene in patients with-hormone refractory prostate cancer. The phase II trials were to be conducted at two centers in Canada and the US [&lt;ulink linkID="399522" linkType="reference"&gt;399522&lt;/ulink&gt;], [&lt;ulink linkID="436768" linkType="reference"&gt;436768&lt;/ulink&gt;]. By May 2001, 75% of patients had been enrolled in the study [&lt;ulink linkID="409567" linkType="reference"&gt;409567&lt;/ulink&gt;] and by June 2002, recruitment was completed. The trial was evaluating the use of tesmilifene in combination with &lt;ulink linkID="11519" linkType="Drug"&gt;mitoxantrone&lt;/ulink&gt; and prednisone. At the 38th ASCO meeting in May 2002, a 70% objective pain response rate was reported in 27 evaluable patients. In addition, 15 patients (56%) had a greater than 50% reduction in prostate specific antigen levels (48% had a greater than 75% reduction) [&lt;ulink linkID="456169" linkType="reference"&gt;456169&lt;/ulink&gt;]. Similar data were published in November 2005 [&lt;ulink linkID="628609" linkType="Reference"&gt;628609&lt;/ulink&gt;], [&lt;ulink linkID="628620" linkType="Reference"&gt;628620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 1996, tesmilifene had demonstrated activity in a phase II trial as combination therapy in patients with hormonally resistant prostate cancer [&lt;ulink linkID="218937" linkType="reference"&gt;218937&lt;/ulink&gt;]. Tesmilifene, in combination with cyclophosphamide, appeared to potentiate the actions of the cytotoxin in malignant cells, while protecting healthy cells in the gut, bone marrow and hair follicles from cyclophosphamide's toxic actions [&lt;ulink linkID="219996" linkType="reference"&gt;219996&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;GASTRIC CANCER&lt;/subtitle&gt; In June 2006, Health Canada approved a phase II trial of tesmilifene in combination with anthracycline, 5-FU and cisplatin for the treatment of first-line inoperable gastric cancer. The randomized study would be conducted in North America and Korea and would enroll up to 120 patients [&lt;ulink linkID="671622" linkType="Reference"&gt;671622&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2005, Shin Poong was planning to initiate clinical trials of a combination of   tesmilifene and doxorubicin in patients with gastric cancer in East Asia [&lt;ulink linkID="582289" linkType="Reference"&gt;582289&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2007, preclinical data were presented at the 98th Annual AACR meeting in Los Angeles, CA,  from a study in drug-resistant breast carcinoma and head and neck squamous cell carcinoma cell lines which  showed that the drug enhanced  the cytotoxicity of docetaxel, paclitaxel, &lt;ulink linkID="13022" linkType="Drug"&gt;epirubicin&lt;/ulink&gt;, doxorubicin, and &lt;ulink linkID="6408" linkType="Drug"&gt;vinorelbine&lt;/ulink&gt;, reducing the IC50 values by up to 50% in most cases [&lt;ulink linkID="784339" linkType="Reference"&gt;784339&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006 preclinical data on tesmilifene were presented at the 97th AACR meeting in Washington DC. The study was aimed to test the drug's ability to increase the cytotoxicity of chemotherapy drugs in rare drug-resistant cells. Tesmilifene in combination with doxorubicin or paclitaxel in wildtype MCF-7 breast tumor cells and isogenic MCF-7 cells resistant to doxorubicin or paclitaxel (MCF-7DOX and MCF-7TAX) decreased the concentration at which 50% of MCF-7TAX cells were killed by paclitaxel, dose dependently by ~ 4-fold (at 6 microM), while having little effect or increasing the IC50 value for paclitaxel in wildtype MCF-7 cells. Similar data were obtained for cross-resistance to doxorubicin in MCF-7TAX cells. The IC50 values for doxorubicin was decreased by as much as 2.5-fold upon the addition of tesmilifene to MCF-7DOX cells with little change in the IC50 value for doxorubicin in wildtype cells. While accumulation of paclitaxel or doxorubicin was reduced in MCF-7TAX and MCF-7DOX cells, respectively, tesmilifene (3 microM) had no effect on the uptake of paclitaxel or doxorubicin into MCF-7, MCF-7TAX, and MCF-7DOX cells [&lt;ulink linkID="659380" linkType="Reference"&gt;659380&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, preclinical data on tesmilifene were presented at the 96th AACR meeting in Anaheim, CA. Paired cell lines (HN-5a and HN-5a/V15e; HL-60 and HL-60/MX2; and HT-29 and HT-29/carbo-15d), where the parent cell line was drug-sensitive and the derivative was drug-resistant, were treated with tesmilifene. Treatment of HN-5a/V15e cells, which express P-glycoprotein, sensitized the cells to docetaxel, doxorubicin and epirubicin. Tesmilifene sensitized HL-60/MX2, which has altered topoisomerase II and overexpresses multidrug resistant proteins, to docetaxel, and sensitized HT-29/carbo-15d cells (resistant to platinum drugs) to cisplatin and to 5-fluorouracil [&lt;ulink linkID="593558" linkType="Reference"&gt;593558&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In January 2006, YM licensed Taiwanese rights to the drug to &lt;ulink linkID="29954" linkType="Company"&gt;TTY Biopharm&lt;/ulink&gt; [&lt;ulink linkID="752992" linkType="Reference"&gt;752992&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2005, YM  and &lt;ulink linkID="19896" linkType="Company"&gt;Shin Poong&lt;/ulink&gt;  entered into an agreement to expand the development of tesmilifene into gastric cancer, as well as into East Asia. Shin Poong would  fund gastric cancer trials and provide YM with upfront, milestone and royalty payments. It would also conduct a bridging study of the drug in breast cancer in Korea [&lt;ulink linkID="582289" linkType="Reference"&gt;582289&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 1996, tesmilifene was licensed by Bristol-Myers Squibb (BMS) from the &lt;ulink linkID="20614" linkType="Company"&gt;University of Manitoba&lt;/ulink&gt; and the Manitoba Cancer Treatment and Research Center [&lt;ulink linkID="218937" linkType="reference"&gt;218937&lt;/ulink&gt;]. In November 2000, York Medical acquired exclusive rights to the product [&lt;ulink linkID="389716" linkType="reference"&gt;389716&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24845">YM BioSciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-09-24T00:00:00.000Z</StatusDate><Source id="832655" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24845">YM BioSciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="127">Stomach tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-09-24T00:00:00.000Z</StatusDate><Source id="832655" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24845">YM BioSciences Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-09-24T00:00:00.000Z</StatusDate><Source id="832655" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24845">YM BioSciences Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-09-24T00:00:00.000Z</StatusDate><Source id="832655" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15123">Bristol-Myers Squibb Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-11-15T00:00:00.000Z</StatusDate><Source id="389716" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24845">YM BioSciences Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="202">Liver tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-09-24T00:00:00.000Z</StatusDate><Source id="832655" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24845">YM BioSciences Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-09-24T00:00:00.000Z</StatusDate><Source id="832655" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24845">YM BioSciences Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-09-24T00:00:00.000Z</StatusDate><Source id="832655" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15123">Bristol-Myers Squibb Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-11-15T00:00:00.000Z</StatusDate><Source id="389716" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-03-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19896">Shin Poong Pharmaceutical Co Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-03-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19896">Shin Poong Pharmaceutical Co Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-03-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="202">Liver tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-03-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20614">University of Manitoba</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-20T00:00:00.000Z</StatusDate><Source id="218937" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20614">University of Manitoba</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-20T00:00:00.000Z</StatusDate><Source id="218937" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15123">Bristol-Myers Squibb Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-20T00:00:00.000Z</StatusDate><Source id="218937" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15123">Bristol-Myers Squibb Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-20T00:00:00.000Z</StatusDate><Source id="218937" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24845">YM BioSciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-10-01T00:00:00.000Z</StatusDate><Source id="467710" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24845">YM BioSciences Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-03-31T00:00:00.000Z</StatusDate><Source id="529777" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24845">YM BioSciences Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-03-31T00:00:00.000Z</StatusDate><Source id="529777" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24845">YM BioSciences Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-01-30T00:00:00.000Z</StatusDate><Source id="761775" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24845">YM BioSciences Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-01-30T00:00:00.000Z</StatusDate><Source id="761775" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24845">YM BioSciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-02-22T00:00:00.000Z</StatusDate><Source id="399522" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24845">YM BioSciences Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-11-15T00:00:00.000Z</StatusDate><Source id="389716" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24845">YM BioSciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-01-31T00:00:00.000Z</StatusDate><Source id="582289" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24845">YM BioSciences Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="202">Liver tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-12-20T00:00:00.000Z</StatusDate><Source id="752992" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24845">YM BioSciences Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-12-20T00:00:00.000Z</StatusDate><Source id="752992" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19896">Shin Poong Pharmaceutical Co Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-01-28T00:00:00.000Z</StatusDate><Source id="582289" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19896">Shin Poong Pharmaceutical Co Ltd</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-01-31T00:00:00.000Z</StatusDate><Source id="582289" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="202">Liver tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-12-20T00:00:00.000Z</StatusDate><Source id="752992" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29954">TTY Biopharm Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-12-20T00:00:00.000Z</StatusDate><Source id="752992" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="24845">YM BioSciences Inc</OwnerCompany><Country id="US">US</Country><Indication id="49">Breast tumor</Indication><AwardedIndication>Treatment of advanced breast cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-02-13T00:00:00.000Z</MileStoneDate><Source id="649947" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00919"><Name>Histamine receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1063427">Pharm-Olam International</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16450">Gilead Sciences Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="19896">Shin Poong Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20614">University of Manitoba</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29954">TTY Biopharm Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCN(CC)CCOc1ccc(cc1)Cc2ccccc2</Smiles><Smiles>CCN(CC)CCOc1ccc(cc1)Cc2ccccc2.Cl</Smiles></StructureSmiles><Deals><Deal id="107634" title="Shin Poong Pharmaceutical and YM BioSciences to codevelop tesmilifene for gastric cancer"></Deal><Deal id="109441" title="YM BioSciences and TTY Biopharm to codevelop tesmilifene in Taiwan "></Deal><Deal id="119934" title="Bristol-Myers Squibb to develop Manitoba University's tesmilifene "></Deal><Deal id="238465" title="Pharm-Olamto to provide clinical trila services to YM BioSciences's tesmilifene for breast cancer   "></Deal><Deal id="238466" title="CRO for Docetaxel plus Tesmilifene (YMB1002)"></Deal></Deals><PatentFamilies><PatentFamily id="1241688" number="WO-09418961" title="Cancer treatment."></PatentFamily><PatentFamily id="1245741" number="US-20040220281" title="Treatment of hormone-refractory prostate cancer"></PatentFamily><PatentFamily id="1830300" number="WO-09211035" title="Improved treatment method for cancer."></PatentFamily><PatentFamily id="2089352" number="EP-00153160" title="Novel Cytotoxic Aminoalkyl Phenol Ethers"></PatentFamily><PatentFamily id="3616112" number="WO-2017072773" title="Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer"></PatentFamily><PatentFamily id="494566" number="WO-03039526" title="Treatment of breast cancer"></PatentFamily><PatentFamily id="622040" number="WO-03037318" title="Use of n,n-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vincent Research &amp; Consulting Inc" id="1042997"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jay Pharma Inc" id="1171199"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gilead Sciences Inc" id="16450"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shin Poong Pharmaceutical Co Ltd" id="19896"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Manitoba" id="20614"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>